The estimated Net Worth of Perry A Karsen is at least $25.7 Миллион dollars as of 17 December 2020. Mr. Karsen owns over 88,764 units of Intellia Therapeutics Inc stock worth over $1,897,783 and over the last 13 years he sold NTLA stock worth over $23,569,610. In addition, he makes $256,497 as Independent Director at Intellia Therapeutics Inc.
Sign up
Mr. Karsen NTLA stock SEC Form 4 insiders trading
Perry has made over 27 trades of the Intellia Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 88,764 units of NTLA stock worth $1,637,696 on 17 December 2020.
The largest trade he's ever made was exercising 118,008 units of Intellia Therapeutics Inc stock on 2 August 2013 worth over $5,312,720. On average, Perry trades about 8,673 units every 29 days since 2012. As of 17 December 2020 he still owns at least 93,764 units of Intellia Therapeutics Inc stock.
You can see the complete history of Mr. Karsen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Perry Karsen biography
Perry A. Karsen is no longer serves as Independent Director of the Company effective 12/31/2020. Mr. Karsen is the Chairman of the Board of the company. From May 2013 to December 2015, Mr. Karsen served as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, a global biopharmaceutical company. Mr. Karsen served as chief operations officer and executive vice president of Celgene from July 2010 to May 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Between February 2009 and July 2010, Mr. Karsen was chif executive officer of Pearl Therapeutics, Inc., a privately held biotechnology company that was subsequently acquired by AstraZeneca plc. Prior to his tenure with Celgene, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a biopharmaceutical company subsequently acquired by GlaxoSmithKline, Bristol-Myers Squibb Co., a biopharmaceutical company, Genentech, Inc., a member of the Roche Group, and Abbott. In addition, Mr. Karsen previously served as a general partner at Pequot Ventures, a venture capital firm. Mr. Karsen serves on the board of directors of the following public companies: OncoMed Pharmaceuticals, Inc., Jounce Therapeutics, Inc. and Voyager Therapeutics, Inc. Within the last five years, he has served on the board of directors of Agios Pharmaceuticals, Inc., Navidea Biopharmaceuticals, Inc. and Alliqua BioMedical, Inc. He also serves on the board of directors of Pliant Therapeutics, Inc., the Gladstone Foundationand the Sonoma Land Trust. He is a past member of the board of directors and a past member of the executive committee of the Biotechnology Innovation Organization and the board of directors of the Alliance for Regenerative Medicine. Mr. Karsen received a masters of management degree from Northwestern University’s Kellogg Graduate School of Management, a masters of arts in teaching of biology from Duke University and a B.S. in biological sciences from the University of Illi
What is the salary of Perry Karsen?
As the Independent Director of Intellia Therapeutics Inc, the total compensation of Perry Karsen at Intellia Therapeutics Inc is $256,497. There are 11 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
How old is Perry Karsen?
Perry Karsen is 65, he's been the Independent Director of Intellia Therapeutics Inc since 2020. There are 1 older and 18 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
What's Perry Karsen's mailing address?
Perry's mailing address filed with the SEC is C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Intellia Therapeutics Inc
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela и Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
What does Intellia Therapeutics Inc do?
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
What does Intellia Therapeutics Inc's logo look like?
Complete history of Mr. Karsen stock trades at Agios Pharmaceuticals Inc, Intellia Therapeutics Inc, Jounce Therapeutics Inc, Voyager Therapeutics Inc и Navidea Biopharmaceuticals Inc
Intellia Therapeutics Inc executives and stock owners
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Laura Sepp-Lorenzino,
Executive Vice President, Chief Scientific Officer -
Andrew Schiermeier,
Chief Operating Officer, Executive Vice President -
Dr. John M. Leonard,
Pres, CEO & Director -
John Leonard,
President, Chief Executive Officer, Director -
José E. Rivera,
Exec. VP, Gen. Counsel & Company Sec. -
Jose Rivera,
Executive Vice President, General Counsel -
Dr. Laura Sepp-Lorenzino,
Exec. VP & Chief Scientific Officer -
Glenn G. Goddard,
Exec. VP, CFO & Treasurer -
Frederick Cohen,
Independent Director -
Glenn Goddard,
Chief Financial Officer, Executive Vice President -
Dr. David Lebwohl M.D.,
Exec. VP & Chief Medical Officer -
Perry Karsen,
Independent Director -
Caroline Dorsa,
Independent Director -
Frank Verwiel,
Independent Chairman of the Board -
Jesse Goodman,
Independent Director -
Jean-Francois Formela,
Independent Director -
Lina Li,
Senior Manager, Investor Relations -
John Crowley,
Independent Director -
David Lebwohl,
Executive Vice President, Chief Medical Officer -
Dr. Rodolphe Barrangou M.B.A., Ph.D.,
Founder & Member of Scientific Advisor Board -
Dr. Jennifer A. Doudna Ph.D.,
Founder & Member of Scientific Advisor Board -
Dr. Rachel E. Haurwitz Ph.D.,
Co-Founder -
Dr. Derrick J. Rossi,
Founder & Member of Scientific Advisor Board -
Dr. Jennifer A. Doudna,
Founder & Member of Scientific Advisor Board -
Andrew May Ph.D.,
Founder and Member of Scientific Advisor Board -
Rachel Haurwitz Ph.D.,
Co-Founder -
Nessan Bermingham Ph.D.,
Founder & Member of Scientific Advisor Board -
William J Chase,
-
Fred E Cohen,
-
Muna Bhanji,
-
Carl L Gordon,
Director -
Institutes For Bio Medical ...,
-
Advisors Llc Orbi Med Capit...,
-
Graeme Bell,
EVP, Chief Financial Officer -
Venture Associates Ix, L.P....,
-
Nicole Heifner,
SVP, Accounting -
Thomas M. Barnes,
SVP, R&D eXtellia -
Therapeutics Holdco, Llc Ca...,
-
Nessan Bermingham,
President & CEO -
David V Morrissey,
SVP, Platform & Delivery Tech -
Venture Fund Ix, L.P.Atlas ...,
-
Holdings (Private) Ltd Full...,
-
Rachel E. Haurwitz,
Director -
Bros. Advisors Lpbaker Feli...,
-
Georgia Keresty,
-
Brian Goff,
-
Moncef Slaoui,
Director -
James Basta,
EVP, General Counsel -
Biosciences, Inc. Caribou,
-
Derek Hicks,
EVP, Chief Business Officer -
Eliana Clark,
EVP, Chief Technical Officer -
Michael P Dube,
VP, PAO and Interim PFO -
Edward J Iii Dulac,
EVP, Chief Financial Officer